BiotechTube

EB612 (EBP05) + NATPARA/NATPAR

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypoparathyroidism

Conditions

Hypoparathyroidism

Trial Timeline

Jun 17, 2018 → Feb 24, 2019

NCT ID
NCT03516773

About EB612 (EBP05) + NATPARA/NATPAR

EB612 (EBP05) + NATPARA/NATPAR is a phase 2 stage product being developed by Entera Bio for Hypoparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT03516773. Target conditions include Hypoparathyroidism.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03516773Phase 2Completed

Competing Products

9 competing products in Hypoparathyroidism

See all competitors
ProductCompanyStageHype Score
MBX 2109MBX BiosciencesPhase 2
47
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injectionMBX BiosciencesPhase 2
47
PCO371 + PlaceboChugai PharmaceuticalPhase 1
33
recombinant human somatotropinEli LillyPre-clinical
23
PalopegteriparatideAscendis PharmaPre-clinical
20
Palopegteriparatide (TransCon PTH)Ascendis PharmaPre-clinical
20
PalopegteriparatideAscendis PharmaPre-clinical
20
EnteraBio's Oral Parathyroid Hormone (1-34)Entera BioPhase 2
44
EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4 + EBP11-F1 + EBP11-F5Entera BioPhase 1
25

Other Products from Entera Bio

EnteraBio's Oral Parathyroid Hormone (1-34)Phase 2
44
EBP05 + Placebo of EBP05Phase 2
44
EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4 + EBP11-F1 + EBP11-F5Phase 1
25
Teriparatide + Oral PTH (1-34)Phase 1
25
Teriparatide + Teriparatide + placeboPhase 1
25